Digital Twin-Guided Patient Specific Rotor Ablation for Persistent Atrial Fibrillation: The CUVIA Trial

Digital Twin-Guided Patient Specific Rotor Ablation for Persistent Atrial Fibrillation: The CUVIA Trial

The CUVIA trial demonstrated that among patients undergoing first ablation for persistent atrial fibrillation (AF), digital twin–guided rotor ablation in addition to pulmonary vein isolation (PVI) reduced the relative risk of atrial arrhythmia recurrence by 48% compared with conventional PVI, according to a study presented by Dr. Daehoon Kim, Yonsei University College of Medicine, Korea, in the Hot Line session at ESC Congress 2025.

The CUVIA trial enrolled 304 patients from four hospitals in Korea who were undergoing initial ablat...
Continue reading this article
Select an option below:
Go beyond the guidelines
A portal site of complex catheter intervention techniques
About TCROSS NEWS Global

TCROSS NEWS Global is an online medical journal that provides valuable information on Cardiovascular medicine to medical professionals worldwide.
We bring you the latest findings and trends in all areas of cardiovascular medicine. Please register and subscribe for unlimited access to quality Cardiovascular News!

Introducing the main contents
Conference Reports
Conference Reports
Timely delivery of scientific meetings from around the world, including AHA, ESC, TCT, EuroPCR, JCC, etc!
Complex PCI Cases
Complex PCI Cases
Features case reports on patients with complex lesions encountered in daily clinical practice.
Live Demonstration Courses
Live Demonstration CoursesComing soon
In this section you will find live videos of catheter interventions for complex lesions.
What is TCROSS NEWS GLOBAL?
TCROSS NEWS Global, an affiliate of TCROSS Co., Ltd. Japan(established in 2005) is a cardiovascular news website which serves as a link between cardiologists, medical device manufacturers and industry stakeholders.
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.
Learn more about TCROSS NEWS Global
This website is automatically translated using Google Translate.

Recommendations

Inclisiran-based Strategy Versus Individually Optimized Lipid-lowering Therapy: The VICTORION-Difference Study
Inclisiran-based Strategy Versus Individually Optimized Lipid-lowering Therapy: The VICTORION-Difference Study
ESC 2025
Tailored Antiplatelet Therapy in High-Risk Patients Undergoing Complex PCI: The TAILORED-CHIP Trial
Tailored Antiplatelet Therapy in High-Risk Patients Undergoing Complex PCI: The TAILORED-CHIP Trial
ESC 2025
Timing of Complete Revascularization During Index Hospitalisation in Patients With STEMI and Multivessel Disease: The OPTION-STEMI Trial
Timing of Complete Revascularization During Index Hospitalisation in Patients With STEMI and Multivessel Disease: The OPTION-STEMI Trial
ESC 2025
3-Month vs 12-Month DAPT After ACS: The DUAL-ACS Trial
3-Month vs 12-Month DAPT After ACS: The DUAL-ACS Trial
ESC 2025
PICK UP
Challenging Healthcare Marketing Costs toward Achieving Universal Health Coverage
Special
InsighTCROSS
Outcomes of PCI for CTO in Dialysis Patients: Insights From the Japanese CTO-PCI Expert Registry
CCI
Outcomes of PCI for CTO in Dialysis Patients: Insights From the Japanese CTO-PCI Expert Registry
Association Between Stent-Edge Hinge Motion and Calcified Nodule Formation in Stent-Edge Calcified Coronary Lesions
Circ Intervention
Association Between Stent-Edge Hinge Motion and Calcified Nodule Formation in Stent-Edge Calcified Coronary Lesions
Aspirin-Free Strategy in High Bleeding Risk ACS and Non-ACS Patients Undergoing PCI: A Subgroup Analysis of the STOPDAPT-3 Trial
Circ Intervention
Aspirin-Free Strategy in High Bleeding Risk ACS and Non-ACS Patients Undergoing PCI: A Subgroup Analysis of the STOPDAPT-3 Trial
Digital Twin-Guided Patient Specific Rotor Ablation for Persistent Atrial Fibrillation: The CUVIA Trial
ESC 2025
Digital Twin-Guided Patient Specific Rotor Ablation for Persistent Atrial Fibrillation: The CUVIA Trial